Paul Hudson, Sanofi CEO (Cyril Marcilhacy/Bloomberg via Getty Images)
Paul Hudson has spotlighted vaccines, immunology and dermatology as some of the top R&D focuses at Sanofi. His latest deal brings all of them together.
The French pharma giant isn’t sharing any financial details about the buyout of Origimm, a low-profile, private Austrian biotech whose technology promises to identify antigens causing skin disease and build vaccines against them. Their lead candidate targets acne vulgaris.
Unlock this story instantly and join 124,300+ biopharma pros reading Endpoints daily — and it’s free.
While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.
Stéphane Bancel, Moderna CEO
Even as public health officials remain guarded about their comments on the likelihood Omicron will escape the reach of the currently approved Covid-19 vaccines, there’s growing scientific consensus that we’re facing a variant that threatens to overwhelm the vaccine barricades that have been erected.
Stéphane Bancel, the CEO of Moderna, one of the leading mRNA players whose quick vault into the markets with a highly effective vaccine created an instant multibillion-dollar market, added his voice to the rising chorus early Tuesday. According to Bancel, there will be a significant drop in efficacy when the average immune system is confronted by Omicron. The only question now is: How much?
Unlock this story instantly and join 124,300+ biopharma pros reading Endpoints daily — and it’s free.
The nonprofit Institute for Clinical and Economic Review on Wednesday released a new report highlighting the ways in which payers are generally ensuring fair access to prescription drugs, even when based on a set of criteria set by the nonprofit.
While noting the lack of transparency hindered the report’s results, ICER said that the ‘great majority’ of payer policies in the formularies evaluated are structured in a way to support many key elements of how ICER defines ‘fair access.’
Reshma Kewalramani, Vertex CEO (Vertex via YouTube)
Vertex claimed its second early-stage win of the fall Wednesday, announcing positive results in a small study on a genetically defined form of kidney disease.
The 16-patient, Phase II trial focused on patients with focal segmental glomerulosclerosis, a rare disease where kidneys are unable to filter blood properly. Over 13 weeks on an experimental pill, the level of protein in the patients’ urine fell by an average of 47.6%.
Philip Dormitzer, new GSK global head of vaccines R&D
GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading minds behind Pfizer and BioNTech’s RNA collaboration that led to Covid-19 jab Comirnaty, the British drug giant said Tuesday.
Dormitzer had been with Pfizer for a little more than six years, joining up after a seven-year stint with Novartis, where he reached the role of US head of research and head of global virology for the company’s vaccines and diagnostics unit.
Unlock this story instantly and join 124,300+ biopharma pros reading Endpoints daily — and it’s free.
Since our start in 2016, Endpoints has grown fast while executing our mission to cover biopharma’s most critical developments for industry pros worldwide. As readership has grown, our advertising business has too. Endpoints advertising partners support the mission and engage their desired audiences through announcements on our email and web platforms, brand recognition in our event coverage and sponsorships of Endpoints daily and weekly reports.
In a first, China has featured insulin in its centralized drug procurement program — but the bulk order comes at a sizable cost for multinational pharma players.
Novo Nordisk, Sanofi and Eli Lilly were among eight companies, domestic and foreign, whose insulin products won tenders from the Chinese public hospital system. In exchange, the drugs’ prices were cut, on average, by 48%, saving the medical institutions a collective $1.4 billion on the first batch of 210 million doses, according to state media.
Looking at past test samples, Dutch officials have detected the Omicron variant in cases dating back as far as Nov. 19, adding further evidence that the variant arrived in Europe well before the first cases were detected in South Africa.
The samples in question were taken on Nov. 19 and 23, according to the country’s health institute, RIVM.
‘It is not yet clear whether these people had also visited southern Africa,’ the RIVM said in a statement.
Ugur Sahin, BioNTech CEO (Frank Rumpenhorst/dpa via AP Images)
Whereas some public health officials and biopharma leaders — including Moderna CEO Stéphane Bancel — are sounding the alarm over the new Omicron coronavirus variant, BioNTech chief Ugur Sahin is pressing a more cautious approach.
In interviews Tuesday with the Wall Street Journal and Reuters, Sahin cautioned that little is yet known of the variant’s ability to cause severe Covid-19, and T cell responses among the vaccinated would likely remain strong. Though the biotech is still conducting lab tests to determine whether antibody protection will be diminished, Sahin isn’t pressing the panic button.
https://endpts.com/sanofi-snaps-up-new-vaccine-candidate-and-devises-mrna-game-plan-around-it-but-not-for-what-you-think/
